100 Clinical Results associated with PTP1B inhibitors(Dalian University Of Technology/Second Military Medical University PLA/North China Pharmaceutical Group Corp )

100 Translational Medicine associated with PTP1B inhibitors(Dalian University Of Technology/Second Military Medical University PLA/North China Pharmaceutical Group Corp )

100 Patents (Medical) associated with PTP1B inhibitors(Dalian University Of Technology/Second Military Medical University PLA/North China Pharmaceutical Group Corp )

Literatures (Medical) associated with PTP1B inhibitors(Dalian University Of Technology/Second Military Medical University PLA/North China Pharmaceutical Group Corp )

01 Jan 2024·International Immunopharmacology

Upregulation of PTPN1 aggravates endotoxemia-induced cardiac dysfunction through inhibiting mitophagy

Article

Author: Ma, Heng ; Song, Qixiang ; Wang, KangKai ; Zhu, Lili ; Liu, Ke ; Lan, Zijun ; Wang, Nian ; Qi, Zehong ; Zhang, Huali

OBJECTIVESTo investigate the role of protein tyrosine phosphatase non-receptor type 1 (PTPN1) in mitophagy during sepsis and its underlying mechanisms and determine the therapeutic potential of PTPN1 inhibitors in endotoxemia-induced cardiac dysfunction.METHODSA mouse model of endotoxemia was established by administering an intraperitoneal injection of lipopolysaccharide (LPS). The therapeutic effect of targeting PTPN1 was evaluated using its inhibitor Claramine (CLA). Mitochondrial structure and function as well as the expression of mitophagy-related proteins were evaluated. Rat H9c2 cardiomyocytes were exposed to mouse RAW264.7 macrophage-derived conditioned medium. Cryptotanshinone, a specific p-STAT3 (Y705) inhibitor, was used to confirm the role of STAT3 in PTPN1-mediated mitophagy following LPS exposure. Electrophoretic mobility shift and dual luciferase reporter assays were performed to discern the mechanisms by which STAT3 regulated the expression of PINK1 and PRKN.RESULTSCLA alleviated LPS-induced myocardial damage, cardiac dysfunction, and mitochondrial injury and dysfunction in the mouse heart. PTPN1 upregulation exacerbated LPS-induced mitochondrial injury and dysfunction in H9c2 cardiomyocytes, but inhibited LPS-induced mitophagy. LPS promoted the interaction between PTPN1 and STAT3 and reduced STAT3 phosphorylation at Tyr705 (Y705), which was required to inhibit mitophagy by PTPN1. Upon LPS stimulation, PTPN1 negatively regulated the transcription of PINK1 and PRKN through dephosphorylation of STAT3 at Y705. STAT3 regulated the transcription of PINK1 and PRKN by binding to STAT3-responsive elements in their promoters.CONCLUSIONPTPN1 upregulation aggravates endotoxemia-induced cardiac dysfunction by impeding mitophagy through dephosphorylation of STAT3 at Y705 and negative regulation of PINK1 and PRKN transcription.

01 May 2023·European Journal of Pharmacology

A comprehensive overview of PPM1B: From biological functions to diseases

Review

Author: Zeng, Kewu ; Zhou, Qian ; Chen, Ruoyu ; Li, Zhongyao ; Lu, Zhiyuan ; Zhao, Baobing ; Li, Yanxia ; Zhao, Huanxin

Reversible phosphorylation of proteins is an important mechanism that regulates cellular processes, which are precisely regulated by protein kinases and phosphatases. PPM1B is a metal ion-dependent serine/threonine protein phosphatase, which regulates multiple biological functions by targeting substrate dephosphorylation, such as cell cycle, energy metabolism, inflammatory responses. In this review, we summarized the occurrent understandings of PPM1B focused on its regulation of signaling pathways, related diseases, and small-molecular inhibitors, which may provide new insights for the identification of PPM1B inhibitors and the treatment of PPM1B-related diseases.

01 Oct 2021·Central Nervous System Agents in Medicinal Chemistry

Pharmacophore Modelling and Virtual Screening Studies for the Discovery of Potential Natural Products Based PDE1B Inhibitor Lead Compounds

Article

Author: Shy, Teng Woei ; Gaurav, Anand

Aim:The aim of the present study was to apply pharmacophore based virtual screening to a natural product database to identify potential PDE1B inhibitor lead compounds for neurodegenerative and neuropsychiatric disorders.Background:Neurodegenerative and neuropsychiatric disorders are a major health burden globally. The existing therapies do not provide optimal relief and are associated with substantial adverse effects. This has resulted in a huge unmet medical need for newer and more effective therapies for these disorders. Phosphodiesterase (PDEs) enzymes have been identified as potential targets of drugs for neurodegenerative and neuropsychiatric disorders, and one of the subtypes, i.e., PDE1B, accounts for more than 90 % of total brain PDE activity associated with learning and memory process, making it an interesting drug target for the treatment of neurodegenerative disorders.Objectives:The present study has been conducted to identify potential PDE1B inhibitor lead compounds from the natural product database.Methods:Ligand-based pharmacophore models were generated and validated; they were then employed for virtual screening of Universal Natural Products Database (UNPD) followed by docking with PDE1B to identify the best hit compound.Results:Virtual screening led to the identification of 85 compounds which were then docked into the active site of PDE1B. Out of the 85 compounds, six showed a higher affinity for PDE1B than the standard PDE1B inhibitors. The top scoring compound was identified as Cedreprenone.Conclusion:Virtual screening of UNPD using Ligand based pharmacophore led to the identification of Cedreprenone, a potential new natural PDE1B inhibitor lead compound.

100 Deals associated with PTP1B inhibitors(Dalian University Of Technology/Second Military Medical University PLA/North China Pharmaceutical Group Corp )

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Preclinical	China	North China Pharmaceutical Group Aino Co. Ltd.	01 Jan 2012
Diabetes Mellitus, Type 2	Preclinical	China	The Second Military Medical University	-
Diabetes Mellitus, Type 2	Preclinical	China	North China Pharmaceutical Group Corp.	-
Diabetes Mellitus, Type 2	Preclinical	China	Dalian School Enterprise Asset Management Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

PTP1B inhibitors(Dalian University Of Technology/Second Military Medical University PLA/North China Pharmaceutical Group Corp )

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation